Jack Aiello | CureTalks
Jack Aiello of San Jose, California is a leading patient advocate in multiple myeloma. In January of 1995 Jack had a terrible backache. He was diagnosed with multiple myeloma through a blood test. Since that time Jack has had stem cell transplants and clinical trials that have brought him to remission, even if only for a short time. However, ultimately he had a full allogenic (donor stem cells) transplant, resulting in a long-term remission. While he has long-term side effects, Jack's spirit remains high and is very much involved with cancer advocacy organizations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society (LLS) and Myeloma Crowd, all of which provide research dollars and education programs for multiple myeloma. He also served on myeloma committees which focus on developing clinical trials, offering his patient perspective to the National Cancer Institute, SWOG Cancer Research Institute, BMT Clinical Trials Network, and Stanford’s Scientific Review Committee.
Related Talks
Beating Leukemia with Groundbreaking CAR-T Cell Therapy
Dr. Stephan A. Grupp made history when he treated the first child with CAR T cell therapy, Emily Whitehead, who is now more…
Myeloma 2017 – Year in Review with MMRF
The MMRF is pioneering precision medicine initiatives in multiple myeloma. This would help match patients to the most effective therapies based on their…
Targeting Stem Cells in Multiple Myeloma for Improved Outcomes
Multiple myeloma remains incurable despite improved remissions with novel agents. Relapse eventually occurs in the form of drug-resistant disease that carries a dismal…
Dr. Carl June’s CAR-T Cell Journey and the Cancer Treatment Revolution
FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. It reprograms…
Demystifying Stem Cell Transplant for Multiple Myeloma Treatment
In 2017 stem cell transplants remains a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done…